KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Gains from Investment Securities (2017 - 2025)

Amneal Pharmaceuticals has reported Gains from Investment Securities over the past 9 years, most recently at -$1.2 million for Q4 2025.

  • Quarterly results put Gains from Investment Securities at -$1.2 million for Q4 2025, down 4.8% from a year ago — trailing twelve months through Dec 2025 was -$4.7 million (down 159.51% YoY), and the annual figure for FY2025 was -$4.7 million, down 159.51%.
  • Gains from Investment Securities for Q4 2025 was -$1.2 million at Amneal Pharmaceuticals, up from -$1.3 million in the prior quarter.
  • Over the last five years, Gains from Investment Securities for AMRX hit a ceiling of $6.1 million in Q3 2023 and a floor of -$16.7 million in Q4 2023.
  • Median Gains from Investment Securities over the past 5 years was -$1.2 million (2024), compared with a mean of -$1.5 million.
  • Peak annual rise in Gains from Investment Securities hit 530.11% in 2023, while the deepest fall reached 2095.93% in 2023.
  • Amneal Pharmaceuticals' Gains from Investment Securities stood at -$11.4 million in 2021, then soared by 119.56% to $2.2 million in 2022, then tumbled by 851.08% to -$16.7 million in 2023, then soared by 93.4% to -$1.1 million in 2024, then decreased by 4.8% to -$1.2 million in 2025.
  • The last three reported values for Gains from Investment Securities were -$1.2 million (Q4 2025), -$1.3 million (Q3 2025), and -$941000.0 (Q2 2025) per Business Quant data.